Table 6.
Survival without serious adverse events (SAEs) for weighted cohort
| Adverse events | Rituximab | Abatacept | Tocilizumab | |||||
|---|---|---|---|---|---|---|---|---|
| No of events | % surviving without event (95% CI) | No of events | % surviving without event (95% CI) | No of events | % surviving without event (95% CI) | |||
| SAE | 224 | 85.0 (82.5 to 87.2) | 101 | 83.4 (78.5 to 87.2) | 111 | 86.7 (80.6 to 91.1) | ||
| Serious infection | 163 | 89.1 (86.8 to 91.0) | 71 | 88.2 (83.8 to 91.4) | 88 | 89.5 (83.8 to 93.3) | ||
| Death | 34 | 97.7 (96.4 to 98.5) | 26 | 95.7 (92.6 to 97.5) | 14 | 98.3 (94.7 to 99.5) | ||
| Cancer | 42 | 97.1 (95.8 to 98.1) | 14 | 97.6 (94.9 to 98.9) | 12 | 98.5 (94.9 to 99.6) | ||
| MACE | 12 | 99.2 (98.3 to 99.6) | 5 | 99.1 (96.9 to 99.7) | 3 | 99.6 (95.8 to 99.9) | ||
MACE=major adverse cardiovascular event (death of cardiovascular origin, stroke, or myocardial infarction).
Weighted cohort, pseudo-population obtained after inverse probability weighting; SAE: serious adverse event (serious infection, major adverse cardiovascular event, cancer, or death).